<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Weight Regain After Stopping GLP-1: The Honest Timeline — Élan Clinic</title>
  <meta name="description" content="More than 40% of weight lost on semaglutide returns within 28 weeks of stopping. Here's the honest timeline — what the research shows and what actually helps." />
  <link rel="canonical" href="https://elan.clinic/blog/weight-regain-after-stopping-glp1.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/weight-regain-after-stopping-glp1.html" />
  <meta property="og:title" content="Weight Regain After Stopping GLP-1: The Honest Timeline" />
  <meta property="og:description" content="More than 40% of weight lost on semaglutide returns within 28 weeks of stopping. Here's what the research shows and what actually helps." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage Structured Data -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "Weight Regain After Stopping GLP-1: The Honest Timeline",
    "headline": "What actually happens to your weight when you stop GLP-1 medication — the honest timeline",
    "url": "https://elan.clinic/blog/weight-regain-after-stopping-glp1.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "More than 40% of weight lost on semaglutide returns within 28 weeks of stopping. Here's the honest timeline — what the research shows and what actually helps.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/weight-regain-after-stopping-glp1.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "STEP-10: Weight regain after semaglutide discontinuation",
        "isPartOf": { "@type": "Periodical", "name": "Lancet eClinicalMedicine" },
        "datePublished": "2025"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "Long-term weight outcomes after GLP-1 discontinuation",
        "isPartOf": { "@type": "Periodical", "name": "Epic Research" },
        "datePublished": "2025"
      }
    ],
    "breadcrumb": {
      "@type": "BreadcrumbList",
      "itemListElement": [
        {"@type": "ListItem", "position": 1, "name": "Home", "item": "https://elan.clinic/"},
        {"@type": "ListItem", "position": 2, "name": "Articles", "item": "https://elan.clinic/blog.html"},
        {"@type": "ListItem", "position": 3, "name": "Weight Regain After Stopping GLP-1"}
      ]
    }
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body { font-family: 'Inter', sans-serif; background-color: #0D1B2A; color: rgba(232, 228, 222, 0.55); line-height: 1.7; -webkit-font-smoothing: antialiased; }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .gold-line { width: 48px; height: 2px; background: #C5A55A; margin: 28px 0; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ─── Navigation ────────────────────────────────────────────── -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;">
        <a href="/artiklid/kaalutous-parast-glp1-lopetamist.html" style="font-size:0.7rem;">EST</a>
        <a href="/ukk.html" style="font-size:0.7rem;">FIN</a>
        <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a>
      </li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ─── Breadcrumb ────────────────────────────────────────────── -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">Weight Regain After Stopping GLP-1</span>
      </nav>
    </div>
  </div>

  <!-- ─── Article Header ───────────────────────────────────────── -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Weight Regain</span>
        <h1>What actually happens to your weight when you stop GLP-1 medication — the honest timeline.</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            9 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ─── Article Body ──────────────────────────────────────────── -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <p>
          Most people search "will I regain weight after stopping Ozempic" somewhere around 2am. I know, because patients tell me that's exactly when the question hits them — usually a few weeks after their last injection, standing on the bathroom scale, watching a number they haven't seen in months creep back up.
        </p>

        <p>
          This article won't reassure you with vague optimism. It's also not going to scare you into staying on medication forever. What it will do is tell you what the research actually shows, why the biology works the way it does, and what genuinely helps.
        </p>

        <p>
          Understanding the timeline is the first step in managing it. Let's start there.
        </p>

        <hr />

        <h2>The biology doesn't lie — why weight comes back</h2>

        <h3>What GLP-1 actually does while you're on it</h3>

        <p>
          GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) work through several overlapping mechanisms: they slow gastric emptying, which means food stays in your stomach longer and you feel full sooner. They act on satiety centres in the brain — specifically the hypothalamus — to dampen the reward response to food. They also improve insulin sensitivity and reduce post-meal glucose spikes.
        </p>

        <p>
          The result is that most people eat significantly less without feeling deprived. Not because they're fighting hunger harder. Because the medication is changing the signal.
        </p>

        <h3>What happens at the receptor level when you stop</h3>

        <p>
          Here's what the medication does not do: fix the underlying neurobiological architecture that drove the weight gain in the first place. When you stop GLP-1 therapy, the satiety signalling that the medication was providing goes away. Your hypothalamus, which has been operating in a modified state, reverts.
        </p>

        <p>
          Two things happen almost immediately. First, ghrelin — the hormone that signals hunger — surges. Second, leptin resistance (which was partially addressed by weight loss itself) reasserts itself. The metabolic rate, which typically drops somewhat with weight loss, doesn't automatically bounce back. Your body is running at a lower baseline, burning less, while appetite signals are pushing you to eat more.
        </p>

        <p>
          This isn't willpower failure. It's predictable physiology.
        </p>

        <h3>The 8-week trigger point</h3>

        <p>
          Research published in 2025 tracking post-discontinuation patterns found that weight regain typically begins at around <strong>8 weeks after stopping medication</strong>. This aligns with semaglutide's pharmacokinetics — the drug has a long half-life (approximately 7 days), so it takes several weeks to fully clear. By week 8, the medication's effects on appetite regulation have essentially resolved, and the biological pressure toward previous weight reasserts.
        </p>

        <hr />

        <h2>The timeline — what the studies show</h2>

        <h3>STEP-10 data: more than 40% regained within 28 weeks</h3>

        <p>
          The STEP-10 trial, with data published in <em>Lancet eClinicalMedicine</em> in November 2025, followed participants who had successfully completed semaglutide therapy and then discontinued. Within 28 weeks — just over six months — more than 40% of the weight lost had returned on average. This was not a fringe finding. It replicated across multiple cohorts.
        </p>

        <p>
          For tirzepatide (Mounjaro, Zepbound), the SURMOUNT-4 data showed more than 50% rebound over 52 weeks. The pattern is consistent across the GLP-1 class.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">&gt;40%</div>
          <div class="key-stat__label">of weight lost on semaglutide returns within 28 weeks of stopping, according to STEP-10 trial data published in Lancet eClinicalMedicine, November 2025.</div>
        </div>

        <h3>Epic Research (2025): complete regain in nearly one in four</h3>

        <p>
          A September 2025 analysis by Epic Research — one of the largest real-world healthcare databases — tracked long-term outcomes for patients who discontinued GLP-1 medications. At 24 months post-discontinuation: 23% of semaglutide users had experienced complete weight regain. For liraglutide (Saxenda), that figure was 27%. Tirzepatide users fared slightly better at 21%, but the difference is not clinically dramatic.
        </p>

        <p>
          The pooled mean regain across the meta-analysis was <strong>9.69 kg</strong> — which, for most patients who lost 10–20 kg on medication, represents the majority of their progress.
        </p>

        <h3>Why regain slows — the plateau around 12 months</h3>

        <p>
          Not all of the lost weight returns. Research tracking regain over longer periods shows a consistent pattern: weight regain accelerates in the first 4–6 months, then slows significantly, and often plateaus around the 12-month mark. A 2025 meta-regression published on medRxiv estimated that approximately <strong>60% of original weight loss is regained by week 52</strong>.
        </p>

        <p>
          This plateau is not because the body "gives up." It's because a new equilibrium is reached at a higher weight than the medication-assisted low, but lower than the pre-medication high. How much of the loss is preserved depends on several factors we'll return to.
        </p>

        <h3>Individual variation — what determines your trajectory</h3>

        <p>
          The 8-week and 52-week timelines are averages. Individual outcomes vary significantly based on: how much weight was lost and over what period, changes made to diet and exercise during treatment, baseline insulin resistance and metabolic health, and — critically — whether muscle mass was preserved during the weight loss phase.
        </p>

        <p>
          This last point matters more than most people realise.
        </p>

        <hr />

        <h2>Not all regain is equal — the muscle problem</h2>

        <h3>Fat-preferential regain</h3>

        <p>
          Research on body composition post-GLP-1 discontinuation shows something that the scale doesn't capture: what comes back is compositionally different from what was lost. During active semaglutide therapy, approximately 25–39% of lost weight is lean mass (muscle and other metabolically active tissue), not fat. When weight returns after discontinuation, the regain skews heavily toward fat. Studies on tirzepatide withdrawal published in November 2025 found that 82% of cardiovascular health markers improved during treatment had reversed with weight rebound — partly because of this fat-preferential pattern.
        </p>

        <h3>Why muscle mass matters more than the scale number</h3>

        <p>
          If you lose 15 kg on semaglutide — 10 kg fat, 5 kg muscle — and then regain 10 kg, mostly fat, you end up lighter than your starting weight but with a worse body composition. More fat, less muscle, lower resting metabolic rate. This is why many patients who regain weight report feeling worse than before they started — not because the medication caused harm, but because the muscle component of the loss wasn't adequately addressed.
        </p>

        <p>
          This is also why the "Ozempic Aftermath" — everything that happens after the prescription ends — deserves as much clinical attention as the active treatment phase. For more on the body composition question, see our piece on <a href="/blog/muscle-loss-on-semaglutide.html">muscle loss on semaglutide</a>.
        </p>

        <h3>What this means for long-term metabolic health</h3>

        <p>
          Reduced lean mass lowers resting metabolic rate, worsens insulin sensitivity, and increases the risk of sarcopenic obesity — a condition where body fat is disproportionately high relative to lean mass. This is a longevity concern, not just an aesthetic one. Especially for patients over 45, where age-related muscle loss is already an active background process.
        </p>

        <hr />

        <h2>What actually helps — the evidence on minimising rebound</h2>

        <h3>Protein threshold — why 1.2–1.6g/kg matters post-medication</h3>

        <p>
          The single most evidence-backed nutritional intervention for preserving weight loss post-GLP-1 is adequate protein intake. The literature consistently points to <strong>1.2–1.6g of protein per kilogram of body weight per day</strong> as the threshold that preserves lean mass and reduces fat-preferential regain.
        </p>

        <p>
          In practical terms, for an 80kg person, that's 96–128g of protein daily. During active GLP-1 therapy, appetite suppression often makes this difficult to achieve — many patients eat far less total food and inadvertently under-consume protein. After discontinuation, when appetite returns, this becomes both more achievable and more urgent.
        </p>

        <h3>Resistance training during and after GLP-1 therapy</h3>

        <p>
          Resistance training is not optional in this context — it's the closest thing to a clinical countermeasure for fat-preferential regain. Studies consistently show that <strong>2–3 sessions per week of resistance training</strong> during GLP-1 therapy preserves significantly more lean mass than cardio alone or no exercise.
        </p>

        <p>
          After discontinuation, the priority shifts from preservation to rebuilding. Compound movements — squats, deadlifts, rows, presses — applied with progressive overload create the hormonal and mechanical stimulus needed to rebuild lean tissue. The evidence here is clear and consistent.
        </p>

        <h3>Behavioural habits that survived clinical studies</h3>

        <p>
          Beyond protein and resistance training, the research identifies a few behavioural patterns that consistently predict better long-term outcomes: structured meal timing (not necessarily intermittent fasting, but predictable eating patterns), consistent sleep (under 7 hours per night is associated with significantly elevated ghrelin — the hunger hormone — and stalled or reversed weight loss), and ongoing engagement with some form of tracking, however minimal.
        </p>

        <p>
          None of these are dramatic. They're infrastructure.
        </p>

        <h3>When restarting medication is the right call</h3>

        <p>
          This needs to be said without moralising: for many people, restarting GLP-1 therapy is the clinically appropriate response to significant regain. Obesity is a chronic condition. Treating it with a chronic management approach — including medication — is not failure. The evidence supports long-term or intermittent GLP-1 use as a legitimate strategy, particularly for patients with comorbidities where weight maintenance has direct health implications.
        </p>

        <p>
          The decision should be clinical, not emotional. That's a conversation worth having with a physician who understands the full picture.
        </p>

        <hr />

        <h2>A physician's honest summary</h2>

        <p>
          The data on weight regain after stopping GLP-1 medication is sobering, but it's not a reason for despair. What it tells us is that weight management is not a finite game — not something you win once and move on from. It's an ongoing process that requires ongoing tools.
        </p>

        <p>
          Understanding the timeline — that regain begins around week 8, accelerates to about 60% of lost weight by week 52, and then plateaus — gives you something to work with. It means you can plan. It means you're not blindsided.
        </p>

        <div class="pull-quote">
          <p>The patients who navigate this best are the ones who used the GLP-1 period to build habits: protein intake, resistance training, sleep structure. They came off medication with a foundation.</p>
        </div>

        <p>
          If weight has returned after stopping GLP-1 therapy, that's not a character verdict. It's predictable biology meeting a gap in the support structure. The question from here is: what do we build?
        </p>

        <!-- ─── Sources ─────────────────────────────────────────── -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>STEP-10 trial. "Weight regain after semaglutide discontinuation." <em>Lancet eClinicalMedicine</em>, November 2025.</p>
          <p>Epic Research. "Long-term weight outcomes after GLP-1 receptor agonist discontinuation." September 2025.</p>
          <p>SURMOUNT-4. Tirzepatide withdrawal and weight rebound data. 2025.</p>
          <p>medRxiv meta-regression: "Weight regain trajectory after GLP-1 discontinuation." 2025.</p>
        </div>

        <!-- ─── Back Link ──────────────────────────────────────── -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ─── Footer CTA ────────────────────────────────────────────── -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Plan Your Life After GLP-1 Therapy.</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to assess your situation after stopping medication — and build a protocol that protects what you've worked for.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ─── Footer Legal ──────────────────────────────────────────── -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
